ArticleCancer medicine2026
Circulating Sex Hormone Levels and Survival in Men With Esophageal Squamous Cell Carcinoma.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMen with esophageal squamous cell carcinoma (ESCC) have worse survival than women, a disparity in which sex hormones may play a role. Yet, whether circulating sex hormone levels are associated with survival in ESCC remains largely unexplored.
methodsThis prospective cohort study included 402 men with ESCC who underwent curative surgery in 2013-2020, with follow-up until May 1, 2023. Associations between preoperative levels of 11 sex hormone measures and all-cause mortality were assessed using multivariable Cox regression, reporting hazard ratios (HRs) and 95% confidence intervals (CIs), adjusted for age, calendar year of surgery, education, smoking, alcohol consumption, pathologic tumor stage, postoperative complications, and chemo(radio)therapy. Sex hormone measures were analyzed both as quartiles and continuously. Continuous analyses were conducted using z-scores of ln-transformed hormone levels, with HRs interpreted per one standard deviation (SD) increase.
resultsIn the overall cohort, no clear associations were observed after adjustment. In tumor stage-stratified analyses, higher free testosterone index was associated with lower mortality in stage 0-II disease (HR per 1-SD increase, 0.78; 95% CI, 0.62-0.97), whereas higher progesterone levels were associated with higher mortality in stage III-IV disease (HR per 1-SD increase, 1.21; 95% CI, 1.01-1.44), with evidence of effect modification by tumor stage for progesterone (p for interaction = 0.011).
conclusionsPreoperative sex hormone measures showed possible stage-dependent associations with survival in men with ESCC, with higher free testosterone index associated with better survival in stage 0-II disease and higher progesterone levels associated with worse survival in stage III-IV disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.